Kelun-Biotech's Antibody Drug Surpasses Merck in Lung Cancer Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Source: seekingalpha
- Clinical Trial Results: Kelun-Biotech's antibody drug sac-TMT outperformed Merck's Keytruda in a late-stage trial for lung cancer, reducing the risk of disease progression or death by 65%, indicating a significant clinical impact that could reshape first-line treatment options for lung cancer.
- Data Presentation Opportunity: The trial results will be presented at the 2026 American Society of Clinical Oncology Annual Meeting, enhancing Kelun-Biotech's visibility in international markets and laying the groundwork for future market promotion.
- Safety Analysis: Approximately 55% of patients treated with sac-TMT experienced treatment-emergent adverse events classified as Grade 3 or higher, compared to only 31% in the control group, indicating that the drug's tolerability requires further evaluation.
- Market Expansion Potential: Based on OptiTROP-Lung05 data, Kelun-Biotech is seeking priority review in China to expand sac-TMT's label as a first-line therapy for lung cancer, which, if approved, would significantly enhance its market share and competitiveness.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRK?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRK
Wall Street analysts forecast MRK stock price to rise
16 Analyst Rating
11 Buy
5 Hold
0 Sell
Moderate Buy
Current: 115.880
Low
95.00
Averages
119.53
High
139.00
Current: 115.880
Low
95.00
Averages
119.53
High
139.00
About MRK
Merck & Co., Inc. is a global health care company that delivers health solutions through its prescription medicines, including biologic therapies, vaccines and animal health products. Its Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Company sells its human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. It sells these human health vaccines primarily to physicians, wholesalers, distributors and government entities. Its Animal Health segment discovers, develops, manufactures and markets a range of veterinary pharmaceutical and vaccine products, as well as health management solutions and services, for the prevention, treatment and control of disease in all livestock and companion animal species. Its products include KEYTRUDA (pembrolizumab) injection, for intravenous use; WELIREG (belzutifan) tablets, for oral use; Ohtuvayre (ensifentrine) and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
Healthcare Stocks Surge Due to Innovation and Policy Changes
- Strong Sector Performance: The healthcare sector has shown remarkable performance, with the State Street Health Care Select Sector SPDR ETF (XLV) rising 3.3% over the past week, significantly outperforming the S&P 500's 0.5% gain, indicating a robust rebound and renewed investor confidence in healthcare stocks.
- Drug Innovation Driving Prices: Merck (MRK) saw a substantial stock price increase after announcing a lung cancer drug that reduced tumor progression risk by 65% in a Phase 3 study, highlighting the positive impact of ongoing pharmaceutical innovation on stock valuations.
- Favorable Medicare Policies: The Centers for Medicare and Medicaid Services announced that starting in 2027, Eli Lilly's (LLY) GLP-1 drugs will be available to Medicare patients for $50 a month, resulting in a 25% stock price increase for Lilly over three weeks, demonstrating the direct support of policy changes for healthcare stocks.
- Aging Population Trend: The global aging population is driving increased demand for pharmaceuticals, medical devices, and health insurance, positioning the healthcare sector as a focal point for investors seeking growth opportunities in the face of demographic shifts.
See More
Healthcare Sector Sees Best Week in Six Months
- Strong Sector Performance: The State Street Health Care Select Sector SPDR ETF (XLV) rose 3.3% over the past five trading days, significantly outperforming the S&P 500's 0.5% gain, establishing healthcare as the top-performing sector this week and reflecting strong investor confidence in the industry.
- Pharmaceutical Innovation: Merck (MRK) saw its stock rise 5.63% this week after announcing a 65% reduction in tumor progression risk from a lung cancer drug developed with a Chinese partner in a Phase 3 study, highlighting the ongoing innovation within the pharmaceutical sector.
- Favorable Insurance Policies: The Centers for Medicare and Medicaid Services announced that Eli Lilly's (LLY) GLP-1 drugs will be available to Medicare patients for $50 a month starting January 2027, leading to a 25% stock price increase for Lilly over three weeks, showcasing the positive impact of policy changes on company performance.
- Aging Population Trend: The global aging population is driving increased demand for pharmaceuticals and medical services, positioning the healthcare sector for robust growth and attracting investors to healthcare ETFs as a safer investment choice amid economic uncertainties.
See More
U.S. Stocks Close Higher, S&P 500 Approaches 7,500
- Market Performance: The S&P 500 is nearing 7,500, on track for its eighth consecutive week of gains, reflecting strong market performance driven by sectors like healthcare and information technology, indicating investor confidence in economic recovery.
- Stock Dynamics: Merck leads the healthcare sector with encouraging trial results, while Dell's stock surges over 16%, showcasing a robust rebound in tech stocks that may attract more investor interest in these sectors' growth potential.
- Arm Holdings Surge: Arm Holdings rallies nearly 50% this week, and despite trimming shares on Monday, it still locked in a 20% gain, highlighting its significance and growth potential within the portfolio, reflecting optimistic market expectations for its future performance.
- Starbucks AI Project Adjustment: Starbucks has ended an AI program for automating inventory accounting, which may impact its $2 billion cost savings target; however, CEO Brian Niccol is set to discuss this goal at next week's conference, indicating the company's ongoing focus on cost control during its turnaround efforts.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
Computer Manufacturers' Stocks Surge After Lenovo's Strong Report
- Lenovo's Performance Boost: Lenovo reported an 84% increase in AI-related revenue for Q4, leading to a nearly 20% surge in its stock price, which also propelled Dell and HP shares up over 15%, reflecting strong market demand and competitive positioning in AI technology.
- Estee Lauder's Stock Recovery: Estee Lauder's shares rose 10% despite ending merger talks with Puig, indicating robust market performance and a solid position in the cosmetics industry.
- Workday's Strong Results: Workday's stock jumped nearly 4% after posting better-than-expected earnings and raising its full-year margin outlook, showcasing its growth potential in finance and HR software.
- Merck's Drug Breakthrough: Merck's lung cancer treatment, developed in partnership with Kelun-Biotech, demonstrated a 65% reduction in tumor progression risk in a phase 3 study, resulting in a nearly 5% increase in stock price, reinforcing its competitive edge in oncology.
See More
US Stocks Close Higher as Market Sentiment Improves
- Market Recovery: The S&P 500 rose by 0.37% and the Nasdaq 100 by 0.42%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Consumer Sentiment Decline: The University of Michigan's consumer sentiment index was revised down to a record low of 44.8, below the expected 48.2, indicating growing concerns among consumers about the economic outlook, which may impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised upward to 4.8%, exceeding the expected 4.6%, potentially prompting the Federal Reserve to consider interest rate hikes in upcoming meetings, which could pressure the stock market.
- Tech Stocks Lead Gains: Workday's stock surged over 5% after reporting Q1 adjusted EPS of $2.66, surpassing expectations, highlighting strong performance in the software sector and potentially attracting more investor interest in tech stocks.
See More
Healthcare Stocks Surge Due to Innovation and Policy Changes
- Strong Sector Performance: The healthcare sector has shown remarkable performance, with the State Street Health Care Select Sector SPDR ETF (XLV) rising 3.3% over the past week, significantly outperforming the S&P 500's 0.5% gain, indicating a robust rebound and renewed investor confidence in healthcare stocks.
- Drug Innovation Driving Prices: Merck (MRK) saw a substantial stock price increase after announcing a lung cancer drug that reduced tumor progression risk by 65% in a Phase 3 study, highlighting the positive impact of ongoing pharmaceutical innovation on stock valuations.
- Favorable Medicare Policies: The Centers for Medicare and Medicaid Services announced that starting in 2027, Eli Lilly's (LLY) GLP-1 drugs will be available to Medicare patients for $50 a month, resulting in a 25% stock price increase for Lilly over three weeks, demonstrating the direct support of policy changes for healthcare stocks.
- Aging Population Trend: The global aging population is driving increased demand for pharmaceuticals, medical devices, and health insurance, positioning the healthcare sector as a focal point for investors seeking growth opportunities in the face of demographic shifts.
See More
Healthcare Sector Sees Best Week in Six Months
- Strong Sector Performance: The State Street Health Care Select Sector SPDR ETF (XLV) rose 3.3% over the past five trading days, significantly outperforming the S&P 500's 0.5% gain, establishing healthcare as the top-performing sector this week and reflecting strong investor confidence in the industry.
- Pharmaceutical Innovation: Merck (MRK) saw its stock rise 5.63% this week after announcing a 65% reduction in tumor progression risk from a lung cancer drug developed with a Chinese partner in a Phase 3 study, highlighting the ongoing innovation within the pharmaceutical sector.
- Favorable Insurance Policies: The Centers for Medicare and Medicaid Services announced that Eli Lilly's (LLY) GLP-1 drugs will be available to Medicare patients for $50 a month starting January 2027, leading to a 25% stock price increase for Lilly over three weeks, showcasing the positive impact of policy changes on company performance.
- Aging Population Trend: The global aging population is driving increased demand for pharmaceuticals and medical services, positioning the healthcare sector for robust growth and attracting investors to healthcare ETFs as a safer investment choice amid economic uncertainties.
See More
U.S. Stocks Close Higher, S&P 500 Approaches 7,500
- Market Performance: The S&P 500 is nearing 7,500, on track for its eighth consecutive week of gains, reflecting strong market performance driven by sectors like healthcare and information technology, indicating investor confidence in economic recovery.
- Stock Dynamics: Merck leads the healthcare sector with encouraging trial results, while Dell's stock surges over 16%, showcasing a robust rebound in tech stocks that may attract more investor interest in these sectors' growth potential.
- Arm Holdings Surge: Arm Holdings rallies nearly 50% this week, and despite trimming shares on Monday, it still locked in a 20% gain, highlighting its significance and growth potential within the portfolio, reflecting optimistic market expectations for its future performance.
- Starbucks AI Project Adjustment: Starbucks has ended an AI program for automating inventory accounting, which may impact its $2 billion cost savings target; however, CEO Brian Niccol is set to discuss this goal at next week's conference, indicating the company's ongoing focus on cost control during its turnaround efforts.
See More
US Stocks Rise, Nasdaq Hits Weekly High
- Strong Market Performance: The S&P 500 rose by 0.50% and the Nasdaq 100 by 0.73%, with the Dow Jones Industrial Average hitting an all-time high, reflecting optimism about a potential US-Iran peace deal that could boost investor confidence.
- Decline in Consumer Confidence: The University of Michigan's consumer sentiment index was revised down to 44.8, a record low, below the expected 48.2, indicating growing consumer concerns about the economic outlook, which may negatively impact future spending.
- Rising Inflation Expectations: The 1-year inflation expectations for May were revised up to 4.8%, a 9-month high, exceeding the expected 4.6%, which could prompt the Fed to consider interest rate hikes at the upcoming meeting, affecting market liquidity.
- Chip Stocks Lead Gains: Qualcomm's stock surged over 12%, leading the Nasdaq 100, demonstrating ongoing market enthusiasm for semiconductor and AI infrastructure, which may yield higher returns for related companies.
See More
Computer Manufacturers' Stocks Surge After Lenovo's Strong Report
- Lenovo's Performance Boost: Lenovo reported an 84% increase in AI-related revenue for Q4, leading to a nearly 20% surge in its stock price, which also propelled Dell and HP shares up over 15%, reflecting strong market demand and competitive positioning in AI technology.
- Estee Lauder's Stock Recovery: Estee Lauder's shares rose 10% despite ending merger talks with Puig, indicating robust market performance and a solid position in the cosmetics industry.
- Workday's Strong Results: Workday's stock jumped nearly 4% after posting better-than-expected earnings and raising its full-year margin outlook, showcasing its growth potential in finance and HR software.
- Merck's Drug Breakthrough: Merck's lung cancer treatment, developed in partnership with Kelun-Biotech, demonstrated a 65% reduction in tumor progression risk in a phase 3 study, resulting in a nearly 5% increase in stock price, reinforcing its competitive edge in oncology.
See More
